MPI Reasearch Invests in Upgrades and Department Expansions
PTSM: Pharmaceutical Technology Sourcing and Management
MPI Research plans to renovate more than 55,000 square feet of facility space as part of the company’s plan to invest in upgrades and department expansion.
MPI Research, an early-stage drug development contract research organization (CRO) based in Michigan, is investing more than $5 million in a facility renovation to begin in 2016. The company plans to renovate more than 55,000 square feet of facility space.
Ed Amat, executive vice-president of global sales and marketing, says in a press announcement that the expansion reflects the increasing demand for investigational and preclinical pharmaceutical and medical device studies. Amat also says that MPI plans to renovate the company’s clinical pathology lab.
In the upcoming year, MPI hopes to increase the company’s workforce by approximately 10%. The company also plans to expand its surgical department with upgraded suites and additional equipment capabilities.
Source: MPI
Drug Shortages and Complying with FDA’s 21 CFR 211.110 Guidance
April 2nd 2025Susan J. Schniepp, distinguished fellow at Regulatory Compliance Associates, and Rona LeBlanc-Rivera, PhD, principal consultant, Regulatory Affairs at Regulatory Compliance Associates, answer some questions about FDA’s January 2025 21 CFR 211.110 guidance document.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
